Cancer Gene Therapy
Adeno-associated virus is tumoricidal because of inhibited angiogenesis
Published in Gene Therapy Weekly, February 16th, 2006
"Type I interferons (alpha/beta) have significant antitumor activity although their short half-life and systemic side effects have limited their clinical utility. An alternative dosing schedule of continuous, low-level delivery, as is achieved by gene therapy, rather than intermittent, high concentration pulsed-dosing, might avoid the toxicity of interferon while maintaining its antitumor efficacy."
"We have tested a gene therapy approach in murine tumor models to treat malignancies that have shown responsiveness to interferon...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-02-16)
More Articles from Gene Therapy Weekly
- Gene Therapy
Aldehyde dehydrogenase gene targeting produces high acetaldehyde levels - Gene Therapy
Leptin receptor installation improves energy balance and reproductive status of obese females - Gene Therapy
Transcriptional control of therapeutic genes targets proliferating tumor cells - Gene Therapy
Transduction of dendritic cells is enhanced by adeno-associated virus - Stem Cell Research
rAAV transduction determines osteoprogenitor-specific promoter activity in mesenchymal stem cells - Adenovirus Vector
Scientists generated rabbit VH domain antibody specific to c-Met and adenoviral knob protein - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
